PMID- 32338840
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1897-9483 (Electronic)
IS  - 0032-3772 (Linking)
VI  - 130
IP  - 6
DP  - 2020 Jun 25
TI  - The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis 
      of patients with multiple myeloma.
PG  - 483-491
LID - 10.20452/pamw.15316 [doi]
AB  - INTRODUCTION: Prognosis of patients with newly diagnosed multiple myeloma (MM), a 
      third most common hematological cancer, is dependent on baseline cytogenetics. 
      However, little is known about the prognostic significance of cytogenetic 
      evolution (CE) at the time between the diagnosis and relapse of MM. OBJECTIVES: 
      Here, we retrospectively analyzed the prognostic impact of CE detected in a 
      routine interphase fluorescence in situ hybridization (FISH) test in a cohort of 
      patients with MM. PATIENTS AND METHODS: Among 650 patients evaluated with the 
      FISH MM panel at our center between 2014 and 2019, we identified 29 individuals 
      with MM who had been tested twice, at the time of diagnosis and relapse. 
      Cytogenetic evolution was defined as the acquisition or loss of at least 1 
      cytogenetic abnormality at relapse (FISH2) compared with the baseline test result 
      (FISH1). RESULTS: Cytogenetic evolution was seen in 14 patients (48%), whereas 15 
      had stable cytogenetics. Acquired chromosome 17p deletion (del[17p]) was the most 
      common type of CE, found in 7 patients (24%). In univariable analysis, stable 
      cytogenetics predicted longer overall survival (median not reached vs 3.8 years; 
      hazard ratio [HR], 0.15; P = 0.04; median follow‑up of 3.1 years) and longer 
      overall survival after FISH2 (median not reached vs 0.8 years; HR, 0.13; P = 
      0.002; median follow‑up of 0.6 years). In multivariable analysis, acquired 
      del(17p) predicted shorter progression‑free survival and the overall survival 
      after FISH2 (HR, 9.3 and 18.8; P = 0.005 and P = 0.004, respectively). 
      CONCLUSIONS: Presence of CE and, particularly, the acquisition of new del(17p) at 
      relapse, negatively affect the outcome of MM. Therefore, re‑evaluation of FISH at 
      MM relapse should be included in routine clinical practice.
FAU - Salomon-Perzynski, Aleksander
AU  - Salomon-Perzynski A
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine, 
      Warsaw, Poland. salomon.perzynski@gmail.com
FAU - Bluszcz, Aleksandra
AU  - Bluszcz A
AD  - Cytogenetic Laboratory, Department of Diagnostic Hematology, Institute of 
      Hematology and Transfusion Medicine, Warsaw, Poland
FAU - Krzywdzinska, Agnieszka
AU  - Krzywdzinska A
AD  - Immunophenotyping Laboratory, Department of Diagnostic Hematology, Institute of 
      Hematology and Transfusion Medicine, Warsaw, Poland
FAU - Spyra-Gorny, Zofia
AU  - Spyra-Gorny Z
AD  - Department of Hematology and Cancer Prevention, Faculty od Health Sciences, 
      Medical University of Silesia in Katowice, Katowice, Poland
FAU - Jakacka, Natalia
AU  - Jakacka N
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine, 
      Warsaw, Poland
FAU - Barankiewicz, Joanna
AU  - Barankiewicz J
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine, 
      Warsaw, Poland
FAU - Borg, Katarzyna
AU  - Borg K
AD  - Cytogenetic Laboratory, Department of Diagnostic Hematology, Institute of 
      Hematology and Transfusion Medicine, Warsaw, Poland
FAU - Solarska, Iwona
AU  - Solarska I
AD  - Molecular Biology Laboratory, Department of Diagnostic Hematology, Institute of 
      Hematology and Transfusion Medicine, Warsaw, Poland
FAU - Szpila, Tomasz
AU  - Szpila T
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine, 
      Warsaw, Poland
FAU - Pula, Bartosz
AU  - Pula B
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine, 
      Warsaw, Poland
FAU - Grosicki, Sebastian
AU  - Grosicki S
AD  - Department of Hematology and Cancer Prevention, Faculty od Health Sciences, 
      Medical University of Silesia in Katowice, Katowice, Poland
FAU - Jamroziak, Krzysztof
AU  - Jamroziak K
AD  - Department of Hematology, Institute of Hematology and Transfusion Medicine, 
      Warsaw, Poland
LA  - eng
PT  - Journal Article
DEP - 20200427
PL  - Poland
TA  - Pol Arch Intern Med
JT  - Polish archives of internal medicine
JID - 101700960
SB  - IM
CIN - Pol Arch Intern Med. 2020 Jun 25;130(6):473-475. PMID: 32588576
MH  - Cytogenetic Analysis
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Multiple Myeloma/diagnosis/genetics
MH  - Neoplasm Recurrence, Local
MH  - Prognosis
MH  - Retrospective Studies
EDAT- 2020/04/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 10.20452/pamw.15316 [doi]
PST - ppublish
SO  - Pol Arch Intern Med. 2020 Jun 25;130(6):483-491. doi: 10.20452/pamw.15316. Epub 
      2020 Apr 27.